[Dobro]

Heart Failure Performance Measures Not Associated With Improved Clinical Outcomes

January 4, 2007 — Current heart-failure performance measures, with the exception of the prescription of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) at discharge, have little relation to patient mortality or combined mortality/rehospitalization in the first 60 to 90 days after discharge, according to the results of a study published in the January 3 issue of JAMA. The prescription of beta-blockers at discharge, however, while not one of the measures of performance, was associated with the most significant improvement in heart-failure outcomes.
[Ссылки доступны только зарегистрированным пользователям ]